查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138283

2022-2029 年全球全外顯子組測序 (WES) 市場

Global Whole Exome Sequencing [WES] Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球全外顯子組測序 (WES) 市場的增長受到多種因素的推動，例如對罕見病診斷的需求不斷增加、基因組學和下一代測序領域的研發不斷增加，以及對個性化醫療的需求不斷增加。由

全外顯子組測序 (WES) 的日益普及正在推動全球市場的增長。

越來越多地採用新一代測序方法來預測、治療和監測包括癌症在內的各種慢性病，正在推動全球市場的增長。癌症外顯子組測序提供了有關導致腫瘤進展的編碼突變的有價值信息。由於外顯子組占基因組的比例不到 2%，因此癌症外顯子組測序是全基因組測序的一種經濟有效的替代方案。此外，與全基因組方法相比，外顯子組測序提供了更方便的數據集。此外，全外顯子組測序技術的低成本和高速度、全外顯子組測序技術的技術進步以及全球主要研究機構的戰略聯盟也在推動全外顯子組測序市場的增長。例如，2021 年 5 月，Baylor Genetics 推出了 Rapid Trio Whole Exome Sequencing，將周轉時間從 7 天縮短到 5 天。此外，紐約大學的一項研究發現，全外顯子組測序可以預測患者是否對癌症免疫療法有反應。

缺乏熟練的人力和缺乏政府支持是全外顯子組測序 (WES) 全球市場增長的障礙。

然而，熟練專業人員的短缺和對政府補貼的高度依賴正在抑制整個外顯子組測序市場的增長。

行業分析

全球全外顯子組測序 (WES) 市場報告根據波特五力、創新、新產品發布、定價分析等各種行業因素對市場進行了深入分析。

COVID-19 影響分析

COVID-19 為全外顯子組測序 (WES) 市場提供了新機遇。例如，COVID-19 正在推動我們實踐數字護理的新現實。確定特定基因型與感染風險之間的關係表明，迫切需要虛擬護理干預措施，以最大限度地減少大流行期間的干擾並減少獲得醫療保健的機會。此外，大流行後，對數字醫療保健解決方案的資金增加對全球全外顯子組測序 [WES] 市場的增長產生了積極影響。

全球全外顯子組測序 [WES] 市場報告將提供對大約 40 多個市場數據表、45 多個數字和估計 200 頁的訪問。

內容

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 採用率提高
      • 激活研發
    • 限制因素
      • 缺乏熟練的專業人員
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品/服務分類

  • 系統
  • 套件
    • 庫準備工具包
    • 目標豐富工具包
    • 其他
  • 服務內容
    • 測序服務
    • 數據分析（生物信息學）服務
    • 其他服務

第 8 章技術

  • 二代測序
    • 合成方法測序 (SBS)
    • 雜交連接測序 (SBL)
  • 第三代測序儀

第 9 章。按應用程序

  • 藥物發現和藥物開發
  • 診斷
  • 個性化醫療
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • 安捷倫科技公司
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Illumina Inc.
  • Bio-Rad Laboratories Inc.
  • Macrogen Inc.
  • Beijing Genomics Institute
  • Ambry Genetics Corp.
  • Eurofins Scientific Group
  • F. Hoffmann-La Roche AG
  • GENEWIZ Inc.
  • Pacific Biosciences of California Inc.

第13章 DataM

簡介目錄
Product Code: DMPH2134

Market Overview

Whole Exome Sequencing [WES] Market is expected to grow at a CAGR of 18.6% during the forecasting period (2022-2029).

Whole exome sequencing is a commonly used next-generation sequencing (NGS) procedure that involves sequencing protein-coding regions of the genome. The human exome represents less than 2% of the genome but contains about 85% known disease-related variants, making this method a cost-effective alternative to whole-genome sequencing. Exome sequencing is widely used to identify and determine genetic variants causing various diseases, such as Miller syndrome and Alzheimer's disease. It also provides a cost-effective screening approach for the diagnosis of genetic disorders. It presents a less resource-intensive alternative to whole-genome sequencing in several applications, including drug discovery and development.

Market Dynamics

The global whole exome sequencing [WES] market growth is driven by several factors, such as increasing demand for the diagnosis of rare diseases, rising research and development in the genomics and next-generation sequencing field, and growing demand for personalized medicine.

The increasing adoption of Whole Exome Sequencing [WES] propels the global market growth.

The rising adoption of next-generation sequencing methods for predicting, treating, and monitoring various chronic diseases, such as cancer, is boosting the market's growth globally. Sequencing the cancer exome provides valuable information about the coding mutations contributing to tumor progression. As the exome represents less than 2% of the genome, cancer exome sequencing is a cost-effective alternative to whole-genome sequencing. Exome sequencing also produces a more convenient data set compared to whole-genome approaches. In addition, the low cost and high speed associated with whole-exome sequencing technology, technological advancements in whole-exome sequencing techniques, and strategic alliances among leading research institutes globally, are also driving the growth of the whole-exome sequencing market. For instance, In May 2021, Baylor Genetics introduced Rapid Trio Whole Exome Sequencing, reducing its turnaround time from seven to five days. Moreover, according to the New York University research, Whole Exome Sequencing Predicts Whether Patients Respond to Cancer Immunotherapy.

The lack of skilled personnel and deprived government support are hurdles to the global Whole Exome Sequencing [WES] market growth.

However, the lack of skilled professionals and high dependability on government grants are restraining the growth of the whole-exome sequencing market.

Industry analysis.

The global whole exome sequencing [WES] market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, Etc.

COVID-19 Impact Analysis

COVID-19 has provided the Whole Exome Sequencing [WES] market with emerging opportunities. For instance, COVID-19 has encouraged us to practice the new reality of digital care. During the pandemic, it was revealed that there is an urgency for virtual care interventions to reduce the interruptions to a minimum and to minimize compromised access to healthcare, which caused increased focus on the sequencing methods for identification of relationships between particular genotypes with the risk of infection. Furthermore, post-pandemic, there is a rise in funding for digital healthcare solutions, positively impacting the global Whole Exome Sequencing [WES] market growth.

Segment Analysis

The Whole Exome Sequencing [WES] application in personalized medicine is predicted to have the largest global market share during the forecast period (2022-2029).

Personalized medicine is expected to grow at the highest rate during the forecast period (2022-2029). Since it aims to provide tailor-made therapies to individual patients, depending on the molecular basis of the disease, it has become popular over recent years. The rising demand for personalized medicine has created tremendous opportunities in genetic medicine. To exploit these opportunities, novel diagnostic and therapeutic technologies must be developed, resulting in the rapid expansion of the global whole exome sequencing market. Growing research & development in precise detection and diagnosis of the disease is expected to minimize the cost of treating chronic conditions. Advancements in whole genome sequencing and molecular diagnostics have given health sciences a better understanding of the precise nature of diseases and pathways to develop personalized treatments.

Geographical Analysis

The North American region commands the global Whole Exome Sequencing [WES] market during the forecast period (2022-2029).

North America is dominating the global whole exome sequencing [WES] market, accounting for the largest market share in 2021. Because of the increasing prevalence of genetic and chronic disorders, such as Cancer, the aging population, increasing demand for targeted and personalized medicine, advanced technological healthcare framework, and favorable government initiatives. For instance, the American Hospital Association estimated that by 2030 around 170 million Americans will be suffering from at least one chronic disease. Furthermore, Cancer is second among the leading cause of death in the U.S. Every year in the United States, over 1.6 million people are diagnosed with Cancer, and nearly 600,000 die from it, making it the second leading cause of death. In addition, rising research activities and investment is estimated to drive industry size in the coming years. Investments in medical health R&D are on a surge, with an 11.1% growth in spending registered between 2019 to 2020. Moreover, United States (U.S.) medical and health research and development (R&D) investment reached $245.1 billion in 2020.

Competitive Landscape

The global whole exome sequencing market is highly competitive with many players. Some of the major players in the market are Illumina Inc., Bio-Rad Laboratories Inc., Agilent Technologies Inc., Macrogen Inc., Beijing Genomics Institute, Ambry Genetics Corp., Eurofins Scientific Group, F. Hoffmann-La Roche AG, GENEWIZ Inc., Pacific Biosciences of California Inc., among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Whole Exome Sequencing [WES] market globally. For instance, on 5 May 2022, Illumina partnered with Deerfield Management to accelerate drug development. Also, on August 03, 2022, Bio-Rad Acquired Curiosity Diagnostics.

Agilent Technologies, Inc.

Overview:

Agilent Technologies, Inc. is a leading life sciences company that provides instruments, software, services, and consumables for laboratory workflow. Agilent was established in 1999 and is headquartered in Santa Clara, California, United States.

Product Portfolio:

Agilent Technologies, Inc.'s product portfolio for Whole Exome Sequencing [WES] has a SureSelect Human All Exon V8, SureSelect Focused Exome, SureSelect Clinical Research Exome V2 and SureSelect non-human Exomes.

The global whole exome sequencing [WES] market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Increasing Adoption
      • 4.1.1.2. Increased Research and Development
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Skilled Professional
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product & Services

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services Segment
    • 7.1.2. Market Attractiveness Index, By Product & Services Segment
  • 7.2. Systems
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Kits
    • 7.3.1. Library Preparation Kits
    • 7.3.2. Target Enrichment Kits
    • 7.3.3. Others
  • 7.4. Services
    • 7.4.1. Sequencing Services
    • 7.4.2. Data Analysis (Bioinformatics) Services
    • 7.4.3. Others Services

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
    • 8.1.2. Market Attractiveness Index, By Technology Segment
  • 8.2. Second-generation Sequencing
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Sequencing by Synthesis (SBS)
    • 8.2.4. Sequencing by Hybridization and Ligation (SBL)
  • 8.3. Third-generation Sequencing

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Drug Discovery and Development
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostics
  • 9.4. Personalized Medicine
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Agilent Technologies Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Illumina Inc.
  • 12.3. Bio-Rad Laboratories Inc.
  • 12.4. Macrogen Inc.
  • 12.5. Beijing Genomics Institute
  • 12.6. Ambry Genetics Corp.
  • 12.7. Eurofins Scientific Group
  • 12.8. F. Hoffmann-La Roche AG
  • 12.9. GENEWIZ Inc.
  • 12.10. Pacific Biosciences of California Inc.

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us